Abstract:Chronic Myelogenous Leukemia (CML) is one of myeloproliferative disorders characterized by the chromosome translocation (9; 22), which causes the generation of the Bcr-Abl fusion protein. Latter activates a number of signal transducers and transcription factors, thus leading to multi-resistance to chemotherapeutic agents. Introduction of imatinib mesylate (Gleevec) significantly increased CML patients' response but still some of patients got disease progression. Therefore, it still remains a high priority to develop new approaches to treat Bcr-Abl+ leukemia. Aim: We aim to investigate the synergy of bortezomib and arsenic trioxide on inducing the apoptosis on Bcr-Abl+ K562-s as well as K562-r cells, which was sensitive or resistant to imatinib treatment respectively. Material and methods: Bcr-Abl+ K562-s and K562-r cells were chosen to evaluate the drugs' effect. We observed the inhibition of cell growth and cell viability after bortezomib and/or arsenic treatment. Flow cytometric evaluation and western blot analysis were performed to detect the development of apoptosis, the changeable expression of Bcr-Abl protein and the apoptosis-related proteins. Results: K562-s and K562-r cells had different response to imatinib treatment. As expected, 0.25μM of imatinib can inhibit half of K562-s cell growth whereas 10–15 more times of concentration of imatinib were necessary to reach the same inhibitory effect in K562-r cells. Combined bortezomib at 12nM with 1μM of ATO, the concentration inducing 50% of K562-s growth arrest, synergistically induced apoptosis in K562-s cells after 48hrs of cotreatment, confirmed by notable elevation of Annexin V+ cells through flow cytometric analysis, when compared to those in the control or single treatment (p<0.01), and immunoblotting detection of caspase-3 cleavage, degradation of poly-adenosine diphosphate-ribose polymerase (PARP), and decreased expression of Bcr-Abl protein. More surprisingly, 24nM concentration of bortezomib and 2μM of ATO, 2 times of concentration needed for 50% of K562-s cell growth inhibition respectively, inhibited 50% of K562-r cells growth, far less than the increased proportion needed during imatinib treatment. And more of important, although single treatment of bortezomib or ATO had no or little effect on inducing apoptosis, combined treatment significantly induced the apoptosis in K562-r cells (p<0.05), associated with activation of apoptosis-relevant proteins and obvious degradation of Bcr-Abl protein.

Systems Understanding of Synergism Between As4S4 and Imatinib in Treating BCR/ABL Leukemia Model and in Attenuating BCR/ABL Oncoprotein As Well As Related Regulatory Networks

A Systems Biology Understanding Of The Synergistic Effects Of Arsenic Sulfide And Imatinib In Bcr/Abl-Associated Leukemia

Combined Effects Of As4s4 And Imatinib On Chronic Myeloid Leukemia Cells And Bcr-Abl Oncoprotein

Synergistic antileukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signaling.

Imatinib co-loaded targeted realgar nanocrystal for synergistic therapy of chronic myeloid leukemia

Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.

Synergy Between Proteasome Inhibitors And Imatinib Mesylate In Chronic Myeloid Leukemia

Synergistically Cooperation of Bortezomib and Arsenic Trioxide on Chronic Myelogenous Leukemia

Coordination of Intrinsic, Extrinsic, and Endoplasmic Reticulum-Mediated Apoptosis by Imatinib Mesylate Combined with Arsenic Trioxide in Chronic Myeloid Leukemia.

Synergistic Cytotoxicity from Combination of Imatinib and Platinum-Based Anticancer Drugs Specifically in Bcr-Abl Positive Leukemia Cells.

SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.

As 4 S 4 Targets RING-type E3 Ligase C-Cbl to Induce Degradation of BCR-ABL in Chronic Myelogenous Leukemia

CAY10683 and Imatinib Have Synergistic Effects in Overcoming Imatinib Resistance Via HDAC2 Inhibition in Chronic Myeloid Leukemia.

Synergic Effects of Proteasome Inhibitor Ps-341 and Tyrosine Kinase Inhibitor Sti571 on Chronic Myeloid Leukemia Cells and Bcr-Abl Oncoprotein in Vitro and in Vivo.

Arsenic Sulfide Binds C-Cbl To Promote Bcr-Abl Ubiquitination And Degradation In Chronic Myelogenous Leukemia.

[Synergistic Inhibitory Effect of STI571 in Combination with Arsenic Trioxide on a Multidrug-Resistant Leukemia Cell Line Expressing Bcr-Abl].

[Synergistic Effect of Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid with Imatinib on K562 Cells].

Proteasome Inhibitor/Imatinib Combinations Exert Potentiated Antileukemia Efficacy But Not Cardiotoxicity In Chronic Myeloid Leukemia

Synergistic Activity of Imatinib and AR-42 Against Chronic Myeloid Leukemia Cells Mainly Through HDAC1 Inhibition.

[Effect of Csn-B Combined with Imatinib on Apoptosis of Chronic Myeloid Leukemia Cells through Nur77/Pim-1/Drp1 Pathway]

Discovery of Berberine that Targetedly Induces Autophagic Degradation of both BCR-ABL and BCR-ABL T315I through Recruiting LRSAM1 for Overcoming Imatinib Resistance